Middle East Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Radiofrequency, Microwave), By Treatment (Surgical, Laparoscopic), By Application (Liver Cancer), By Country, And Segment Forecasts, 2025 - 2030
Description
Middle East Tumor Ablation Market Summary
The Middle East tumor ablation market size was estimated at USD 50.5 million in 2024 and is projected to reach USD 95.2 million in 2030, growing at a CAGR of 11.1% from 2025 to 2030. The cancer burden in the region, along with increased investments in oncology and the rising demand for non-invasive treatment methods, are the major factors driving this market's growth. The demand for new local treatments using such methods as radiofrequency, microwave, cryoablation, or irreversible electroporation is growing as medical workers look for safer and more effective treatment methods for cancer.
According to a study published in September 2024 by John Wiley & Sons, Inc., the Gulf Cooperation Council (GCC) countries registered 42,475 new cancer cases and 19,895 deaths in 2020. The cancer incidence is predicted to increase by 116% in Saudi Arabia and by up to 270% in Qatar by 2040. This alarming increase underscores the growing need for efficient and less-invasive cancer therapies. Tumor abolition methods that enable the targeted destruction of tumors, with less time needed for recovery and reduced hospital stays, are becoming more popular in the Middle East. As governments and private medical establishments continue to invest in advanced oncology centers and widen the scope of interventional radiology, the Middle East tumor ablation industry will be experiencing high growth in the near future.
Moreover, cancer hospitals and oncology networks, which are often financed by governments and large private healthcare groups in the Middle East, are expanding their capacity, thereby creating a demand for image-guided ablation services. For instance, The Hamdan Bin Rashid Cancer Hospital in Dubai is scheduled to launch in 2026 as part of Dubai Health’s academic health system. In June 2024, Dubai Health collaborated with The Royal Marsden NHS Foundation Trust to expedite clinical development and establish first-class cancer care and research facilities in the region.
Physicians are progressively choosing tumor ablation to treat liver, kidney, lung, and bone tumors as this method is said to be more beneficial than surgery in terms of a shorter hospital stay, quicker recovery, and it is a viable solution when surgery cannot be done. These reasons are attractive to both patients and healthcare payers seeking cost-efficient, high-quality outcomes. Technological advances, such as the reduction in size of ablation probes, the increased speed of the energy delivery system, the enhancement of imaging guidance, and the growing popularity of interventional radiology training, are making operations safer, more accurate, and more reliable. All these factors together enhance the region’s capacity to deliver state-of-the-art, minimally invasive cancer treatments, making tumor ablation a crucial element of modern oncology care.
Middle East Tumor Ablation Market Report Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each sub-segments from 2021 to 2030. For this study, Grand View Research has segmented the Middle East tumor ablation market report based on technology, treatment, and application.
The Middle East tumor ablation market size was estimated at USD 50.5 million in 2024 and is projected to reach USD 95.2 million in 2030, growing at a CAGR of 11.1% from 2025 to 2030. The cancer burden in the region, along with increased investments in oncology and the rising demand for non-invasive treatment methods, are the major factors driving this market's growth. The demand for new local treatments using such methods as radiofrequency, microwave, cryoablation, or irreversible electroporation is growing as medical workers look for safer and more effective treatment methods for cancer.
According to a study published in September 2024 by John Wiley & Sons, Inc., the Gulf Cooperation Council (GCC) countries registered 42,475 new cancer cases and 19,895 deaths in 2020. The cancer incidence is predicted to increase by 116% in Saudi Arabia and by up to 270% in Qatar by 2040. This alarming increase underscores the growing need for efficient and less-invasive cancer therapies. Tumor abolition methods that enable the targeted destruction of tumors, with less time needed for recovery and reduced hospital stays, are becoming more popular in the Middle East. As governments and private medical establishments continue to invest in advanced oncology centers and widen the scope of interventional radiology, the Middle East tumor ablation industry will be experiencing high growth in the near future.
Moreover, cancer hospitals and oncology networks, which are often financed by governments and large private healthcare groups in the Middle East, are expanding their capacity, thereby creating a demand for image-guided ablation services. For instance, The Hamdan Bin Rashid Cancer Hospital in Dubai is scheduled to launch in 2026 as part of Dubai Health’s academic health system. In June 2024, Dubai Health collaborated with The Royal Marsden NHS Foundation Trust to expedite clinical development and establish first-class cancer care and research facilities in the region.
Physicians are progressively choosing tumor ablation to treat liver, kidney, lung, and bone tumors as this method is said to be more beneficial than surgery in terms of a shorter hospital stay, quicker recovery, and it is a viable solution when surgery cannot be done. These reasons are attractive to both patients and healthcare payers seeking cost-efficient, high-quality outcomes. Technological advances, such as the reduction in size of ablation probes, the increased speed of the energy delivery system, the enhancement of imaging guidance, and the growing popularity of interventional radiology training, are making operations safer, more accurate, and more reliable. All these factors together enhance the region’s capacity to deliver state-of-the-art, minimally invasive cancer treatments, making tumor ablation a crucial element of modern oncology care.
Middle East Tumor Ablation Market Report Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each sub-segments from 2021 to 2030. For this study, Grand View Research has segmented the Middle East tumor ablation market report based on technology, treatment, and application.
- Technology Outlook (Revenue, USD Million, 2021 - 2030)
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- HIFU
- Other Ablation Technologies
- Treatment Outlook (Revenue, USD Million, 2021 - 2030)
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
- Application Outlook (Revenue, USD Million, 2021 - 2030)
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer
- Region Outlook (Revenue, USD Million, 2021 - 2030)
- Middle East
- Qatar
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Bahrain
Table of Contents
175 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Treatment
- 1.2.3. Application
- 1.2.4. Regional
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in the Middle East
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Treatment outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Middle East Tumor Ablation Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising incidence of cancer
- 3.2.1.2. Technological advancements in ablation devices
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Stringent regulations & approvals
- 3.2.2.2. Presence of alternative treatment options
- 3.2.3. Market Opportunities Analysis
- 3.2.3.1. Increasing healthcare expenditure in emerging regions
- 3.3. Middle East Tumor Ablation Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- Chapter 4. Middle East Tumor Ablation Market: Technology Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Middle East Tumor Ablation Market: Technology Movement Analysis & Market Share, 2024 & 2030
- 4.3. Radiofrequency Ablation
- 4.3.1. Radiofrequency Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 4.4. Microwave Ablation
- 4.4.1. Microwave Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 4.5. Cryoablation
- 4.5.1. Cryoablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 4.6. Irreversible Electroporation Ablation
- 4.6.1. Irreversible Electroporation Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 4.7. HIFU
- 4.7.1. HIFU Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 4.8. Other Ablation Technologies
- 4.8.1. Other Ablation Technologies Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- Chapter 5. Middle East Tumor Ablation Market: Treatment Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Middle East Tumor Ablation Market: Treatment Movement Analysis & Market Share, 2024 & 2030
- 5.3. Surgical Ablation
- 5.3.1. Surgical Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 5.4. Laparoscopic Ablation
- 5.4.1. Laparoscopic Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 5.5. Percutaneous Ablation
- 5.5.1. Percutaneous Ablation Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- Chapter 6. Middle East Tumor Ablation Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Middle East Tumor Ablation Market: Application Movement Analysis & Market Share, 2024 & 2030
- 6.3. Kidney Cancer
- 6.3.1. Kidney Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 6.4. Liver Cancer
- 6.4.1. Liver Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 6.5. Breast Cancer
- 6.5.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 6.6. Lung Cancer
- 6.6.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 6.7. Prostate Cancer
- 6.7.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- 6.8. Other Cancer
- 6.8.1. Other Cancer Market Revenue Estimates and Forecasts, 2021 - 2030 (USD Million)
- Chapter 7. Middle East Tumor Ablation Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Middle East Tumor Ablation Market: Regional Movement Analysis & Market Share, 2024 & 2030
- 7.2.1. Middle East Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.2. Qatar
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Competitive Scenario
- 7.2.2.3. Regulatory Scenario
- 7.2.2.4. Reimbursement Scenario
- 7.2.2.5. Qatar Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.3. Saudi Arabia
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. Regulatory Scenario
- 7.2.3.4. Reimbursement Scenario
- 7.2.3.5. Saudi Arabia Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.4. UAE
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Competitive Scenario
- 7.2.4.3. Regulatory Scenario
- 7.2.4.4. Reimbursement Scenario
- 7.2.4.5. UAE Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.5. Kuwait
- 7.2.5.1. Key Country Dynamics
- 7.2.5.2. Competitive Scenario
- 7.2.5.3. Regulatory Scenario
- 7.2.5.4. Reimbursement Scenario
- 7.2.5.5. Kuwait Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.6. Oman
- 7.2.6.1. Key Country Dynamics
- 7.2.6.2. Competitive Scenario
- 7.2.6.3. Regulatory Scenario
- 7.2.6.4. Reimbursement Scenario
- 7.2.6.5. Oman Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- 7.2.7. Bahrain
- 7.2.7.1. Key Country Dynamics
- 7.2.7.2. Competitive Scenario
- 7.2.7.3. Regulatory Scenario
- 7.2.7.4. Reimbursement Scenario
- 7.2.7.5. Bahrain Tumor Ablation Market Estimates and Forecasts, 2021 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Key Company Profiles
- 8.2.1. Medtronic
- 8.2.1.1. Company Overview
- 8.2.1.2. Financial Performance
- 8.2.1.3. Product Benchmarking
- 8.2.1.4. Strategic Initiatives
- 8.2.2. Boston Scientific Corporation
- 8.2.2.1. Company Overview
- 8.2.2.2. Financial Performance
- 8.2.2.3. Product Benchmarking
- 8.2.2.4. Strategic Initiatives
- 8.2.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
- 8.2.3.1. Company Overview
- 8.2.3.2. Financial Performance
- 8.2.3.3. Product Benchmarking
- 8.2.3.4. Strategic Initiatives
- 8.2.4. AngioDynamics
- 8.2.4.1. Company Overview
- 8.2.4.2. Financial Performance
- 8.2.4.3. Product Benchmarking
- 8.2.4.4. Strategic Initiatives
- 8.2.5. Bioventus Inc. (Misonix Inc.)
- 8.2.5.1. Company Overview
- 8.2.5.2. Financial Performance
- 8.2.5.3. Product Benchmarking
- 8.2.5.4. Strategic Initiatives
- 8.2.6. EDAP TMS
- 8.2.6.1. Company Overview
- 8.2.6.2. Financial Performance
- 8.2.6.3. Product Benchmarking
- 8.2.6.4. Strategic Initiatives
- 8.2.7. Chongqing Haifu Medical Technology Co., Ltd
- 8.2.7.1. Company Overview
- 8.2.7.2. Financial Performance
- 8.2.7.3. Product Benchmarking
- 8.2.7.4. Strategic Initiatives
- 8.2.8. Mermaid Medical
- 8.2.8.1. Company Overview
- 8.2.8.2. Financial Performance
- 8.2.8.3. Product Benchmarking
- 8.2.8.4. Strategic Initiatives
- 8.2.9. HealthTronics, Inc.
- 8.2.9.1. Company Overview
- 8.2.9.2. Financial Performance
- 8.2.9.3. Product Benchmarking
- 8.2.9.4. Strategic Initiatives
- 8.2.10. H.S. Hospital Service S.p.A
- 8.2.10.1. Company Overview
- 8.2.10.2. Financial Performance
- 8.2.10.3. Product Benchmarking
- 8.2.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
